HCPCS Code Descriptor:
Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg
55513-0164-01, 55513-0132-01, 55513-0141-01
Route of Administration:
KANJINTI is an Oncology Biosimilar drug manufactured by Amgen and administered via the Intravenous route of administration. The Q Code: Q5117 is aligned to the drug KANJINTI.
Kanjinti (trastuzumab) is a HER2 inhibitor that is used to treat certain types of stomach and breast cancer. Kanjinti can be used by itself or in combination with other cancer medications. It is manufactured by Amgen USA and is biosimilar to the medication Herceptin (J9356). Kanjinti has been aligned to the Q Code Q5117 since October 2019.
Access Pricing and More By Registering
HCPCS Added Date:
HCPCS Effective Date:
HCPCS Short Description:
Inj., kanjinti, 10 mg
Billing and Coding Guide: